TN2009000257A1 - Utilisation du 10-[(3r)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine pour la preparation d'un medicament exercant une inhibition selective des recepteurs muscariniques m1, m2 et m3. - Google Patents

Utilisation du 10-[(3r)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine pour la preparation d'un medicament exercant une inhibition selective des recepteurs muscariniques m1, m2 et m3.

Info

Publication number
TN2009000257A1
TN2009000257A1 TNP2009000257A TN2009000257A TN2009000257A1 TN 2009000257 A1 TN2009000257 A1 TN 2009000257A1 TN P2009000257 A TNP2009000257 A TN P2009000257A TN 2009000257 A TN2009000257 A TN 2009000257A TN 2009000257 A1 TN2009000257 A1 TN 2009000257A1
Authority
TN
Tunisia
Prior art keywords
azabicyclo
phenothiazine
ylmethyl
medicament
oct
Prior art date
Application number
TNP2009000257A
Other languages
English (en)
French (fr)
Inventor
Thierry Clerc
Jacky Tisne-Versailles
Christophe Przybylski
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of TN2009000257A1 publication Critical patent/TN2009000257A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TNP2009000257A 2006-12-28 2009-06-23 Utilisation du 10-[(3r)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine pour la preparation d'un medicament exercant une inhibition selective des recepteurs muscariniques m1, m2 et m3. TN2009000257A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0656002A FR2910814B1 (fr) 2006-12-28 2006-12-28 Utilisation du 10-°(r3)-1-azabicyclo°2.2.2!oct-3-ylmethyl!-10h- phenothiazine pour la preparation d'un medicament exercant une inhibition selective des recepteurs muscariniques m1,2,3
PCT/EP2007/064553 WO2008080924A1 (fr) 2006-12-28 2007-12-26 Utilisation du 10-[(3r)-1-azabicyclo[2.2.2]oct-3-ylméthyl]-10h-phénothiazine pour la préparation d'un médicament exerçant une inhibition sélective des récepteurs muscariniques m1, m2 et m3

Publications (1)

Publication Number Publication Date
TN2009000257A1 true TN2009000257A1 (fr) 2010-10-18

Family

ID=37951872

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000257A TN2009000257A1 (fr) 2006-12-28 2009-06-23 Utilisation du 10-[(3r)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine pour la preparation d'un medicament exercant une inhibition selective des recepteurs muscariniques m1, m2 et m3.

Country Status (21)

Country Link
US (1) US8143245B2 (enExample)
EP (1) EP2124956A1 (enExample)
JP (1) JP5564263B2 (enExample)
KR (1) KR101465277B1 (enExample)
CN (1) CN101573120B (enExample)
AR (1) AR064714A1 (enExample)
AU (1) AU2007341274B2 (enExample)
BR (1) BRPI0720591A2 (enExample)
CA (1) CA2674162A1 (enExample)
FR (2) FR2910814B1 (enExample)
IL (1) IL199557A (enExample)
MA (1) MA31026B1 (enExample)
MX (1) MX2009006950A (enExample)
NO (1) NO20092654L (enExample)
NZ (1) NZ577915A (enExample)
RU (1) RU2449794C2 (enExample)
TN (1) TN2009000257A1 (enExample)
TW (1) TWI423806B (enExample)
UA (1) UA98131C2 (enExample)
WO (1) WO2008080924A1 (enExample)
ZA (1) ZA200904304B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015133989A (ja) * 2015-04-28 2015-07-27 重泉 達志 健康食品
KR101969263B1 (ko) 2018-07-16 2019-04-15 이상호 산소 챔버용 산소 공급 장치

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1173445B (it) * 1984-03-16 1987-06-24 Guidotti & C Spa Labor Agenti ad attivita' antibroncospastica e composizioni farmaceutiche che li contengono
IT1251161B (it) * 1991-08-07 1995-05-04 Derivati ammonio quaternari di (-) e (+)-3-(10 h-fenotiazin-10-ilmetil)-l-azabiciclo (2.2.2.)ottano e composizioni farmaceutiche che li contengono
AU6686700A (en) 1999-08-23 2001-03-19 H. Lundbeck A/S Treatment of urinary incontinence
AU2002366800B2 (en) * 2001-12-20 2006-08-03 Femmepharma Holding Company, Inc. Vaginal delivery of drugs

Also Published As

Publication number Publication date
US8143245B2 (en) 2012-03-27
JP2010514730A (ja) 2010-05-06
KR101465277B1 (ko) 2014-11-27
MX2009006950A (es) 2009-07-14
AR064714A1 (es) 2009-04-22
AU2007341274A1 (en) 2008-07-10
RU2009128326A (ru) 2011-02-10
JP5564263B2 (ja) 2014-07-30
RU2449794C2 (ru) 2012-05-10
FR2953721A1 (fr) 2011-06-17
AU2007341274B2 (en) 2012-09-20
HK1133207A1 (en) 2010-03-19
BRPI0720591A2 (pt) 2014-02-25
NZ577915A (en) 2011-12-22
CN101573120A (zh) 2009-11-04
TWI423806B (zh) 2014-01-21
UA98131C2 (ru) 2012-04-25
KR20090103887A (ko) 2009-10-01
WO2008080924A1 (fr) 2008-07-10
NO20092654L (no) 2009-09-28
EP2124956A1 (fr) 2009-12-02
FR2910814B1 (fr) 2011-06-17
CN101573120B (zh) 2011-11-23
TW200833331A (en) 2008-08-16
FR2910814A1 (fr) 2008-07-04
ZA200904304B (en) 2010-06-30
CA2674162A1 (fr) 2008-07-10
US20100063276A1 (en) 2010-03-11
MA31026B1 (fr) 2009-12-01
IL199557A (en) 2014-09-30

Similar Documents

Publication Publication Date Title
TNSN08313A1 (fr) Des formes pharmaceutiques resistantes a la modification
LU92323I2 (fr) La combinaison de (a) dextromethorphan ou un de ses sels pharmaceutiquement acceptables, précursers ou dérivés, par ex. hydrobromure de dextromethorphan et en particulier hydrobromure de dextromethorphan monohydrate;et (b) quinidine ou un de ses selspharmacuetiquement acceptables, précurseurs ou dé rivés, par ex. sulfate de quinidine et en particulier sulfate de quinidine dihydrate
WO2006130522A3 (en) Methods and compositions for managing psychotic disorders
MA32049B1 (fr) Traitement du cancer avec des combinaisons d'inhibiteurs de topoisomerase et d'inhibiteurs de parp
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
MA37711A1 (fr) Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
MA34207B1 (fr) Inhibiteurs de la pi3 kinase et/ou du mtor
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
MX2012004848A (es) Compuestos heterociclicos triciclicos.
MA29799B1 (fr) Administration d'inhibiteurs de dipeptidyl peptidase
MA30765B1 (fr) Derives innovants du thiophene
WO2005020929A3 (en) Sustained release dosage forms of ziprasidone
MA29795B1 (fr) Inhibiteurs de la dipeptidyl peptidase permetttant de traiter le diabete
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
WO2007084560A8 (en) INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH
MA31008B1 (fr) Polymorphes d'un antagoniste du recepteur mglur5
EP2063889A4 (en) SPIROPIPERIDINE BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
MA30781B1 (fr) Inhibiteur de kinase
WO2007126362A8 (en) Compounds that are agonists of muscarinic receptors and that may be effective in treating pain, alzheimer's disease and/or schizophrenia
MA30006B1 (fr) Composes anti-hypercholesterolemiques
WO2007025005A3 (en) Sustained release formulations of nalbuphine
WO2007143557A3 (en) Compounds and methods for treating mammalian gastrointestinal parasitic infections
EP2015753A4 (en) INHIBITION OF HIV INFECTIONS BY CHEMOPROPHYLAXIS
MA32343B1 (fr) Pyrimidyle cyclopentane hydroxylé en tant qu'inhibiteur de protéine kinase akt